Nieuws

In the rare lung disease PCD, the cilia in the lungs do not function properly. As a result, the lungs remain chronically inflamed. In this study, Dr Bahar Arik is developing disease models that will enable her to test future treatments for this rare, hereditary disease.

Alpha-1 is a rare, hereditary, and severe form of COPD. The lungs become damaged because an important protein is missing. Dr. Tjeerd van der Veer aims to detect lung damage caused by this disease at an earlier stage.

Respiratory physician Sami Simons recently asked people both with and without lung disease to make their voices heard—literally. He is now once again asking for your help with his research into detecting COPD exacerbations at an early stage.

Children admitted to hospital with acute breathing difficulties need oxygen less often and for a shorter time than previously thought, according to a large study led by Spaarne Gasthuis.

Professor Coen van Hasselt’s research is an important step towards preventing antibiotic resistance. This is good news for people who frequently develop pneumonia caused by the Pseudomonas bacterium.

Longfonds is giving innovative research into lung diseases a major boost. Through three grants, we are bringing together expertise and working towards better treatments and a healthier future for people with lung disease.

Around 600,000 people in the Netherlands have asthma. For approximately 60,000 of them, the symptoms are severe and difficult to treat. Researchers want to better understand exactly what goes wrong in the lungs of people with asthma. That is why they are creating a detailed map of the lungs: the Lung Atlas.

Voor de tweede keer reiken Longfonds en de Swierenga Stichting samen een speciale subsidie uit voor onderzoek naar zeldzame longziekten: de Longfonds-Swierenga Grant. Met deze unieke impuls van 50.000 euro geven we bevlogen junior-onderzoekers de kans hun innovatieve ideeën verder te brengen.

Zeven jaar geleden startte Longfonds het project BREATH. Internationale toponderzoekers werkten samen aan één doel: longen met COPD repareren. Eind 2025 maakten we de balans op. Wat hebben we in deze zeven jaar bereikt?